IL33 rs634062: What Your Genotype Means
The genetic variant rs634062 is a single-nucleotide polymorphism located in the regulatory region of the IL33 gene on chromosome 9. Research has linked this variant to altered expression of the alarmin cytokine interleukin-33, showing statistical correlations with susceptibility to allergic rhinitis, peanut allergy, and atopic dermatitis. However, current clinical and genetic evidence remains limited, indicating that it represents a modest statistical risk factor rather than a direct cause of disease.
What each genotype means
Typical IL-33 expression
This genotype represents the most common configuration at this location in many populations. Research suggests this version of the gene is associated with baseline levels of IL-33, an immune signaling protein, and does not carry the specific genetic markers linked to increased risk of allergic conditions in some studies.
This is the most frequent genotype in many global populations, though exact percentages vary significantly by ancestry.
Intermediate allergic risk profile
Carrying one copy of the A allele is associated with a statistical increase in the risk of developing allergic rhinitis, peanut allergy, or atopic dermatitis in some studies. This variant is thought to influence the expression of the IL-33 alarmin, which plays a role in immune system activation. Please discuss any concerns regarding allergy symptoms or health history with your clinician.
This heterozygous genotype is common, appearing in roughly 1 in 3 to 1 in 4 individuals in European and East Asian cohorts.
Elevated allergic risk profile
Individuals with two copies of the A allele may have a higher statistical likelihood of experiencing allergic conditions such as atopic dermatitis or peanut allergy compared to those without the variant. This association is linked to potential changes in how the body regulates IL-33, a protein involved in inflammatory responses. This finding is based on limited evidence and should be discussed with a healthcare provider in the context of your overall health.
This genotype is less common than the heterozygous form, typically found in approximately 4% to 9% of individuals in European and East Asian populations.
Genomic Location and Variant Biology
The variant rs634062 represents a common single-nucleotide polymorphism (SNP) situated within the non-coding regulatory architecture of the interleukin-33 (IL33) locus on human chromosome 9. Rather than altering the amino acid sequence of a protein directly, regulatory variants like rs634062 reside near gene promoters or enhancers and often exert their biological effects by modifying transcription factor binding sites, chromatin accessibility, or RNA transcript abundance. As detailed in resources such as [NCBI dbSNP](https://www.ncbi.nlm.nih.gov/snp/rs634062), variations in this region typically consist of an exchange between adenine and guanine (A/G) alleles. Because non-coding variations often sit within wide linkage disequilibrium blocks across the chromosome, rs634062 is regularly co-inherited with neighboring polymorphisms that shape localized regulatory mechanisms in mucosal and barrier tissues.
The Role of Interleukin-33 as an Immune Alarmin
The IL33 gene encodes interleukin-33, a protein member of the interleukin-1 cytokine superfamily. Interleukin-33 functions primarily as an "alarmin," an innate molecular danger signal constitutively expressed and stored within the nuclei of barrier cells such as epithelial cells in the skin, lungs, and gut, as well as endothelial linings. As highlighted in research on [IL-33 biological properties in airway disease](https://pmc.ncbi.nlm.nih.gov/articles/PMC5492954/), when barrier tissue undergoes cellular stress, mechanical damage, or encounters environmental allergens, active IL-33 is rapidly released into the extracellular environment. Once freed, it binds to its cognate ST2 receptor (encoded by IL1RL1) on innate lymphoid cells, mast cells, and T-helper 2 cells, triggering cascades of inflammatory cytokines like IL-4, IL-5, and IL-13 that promote classical type 2 immune defenses.
Research Associations and Evidence Strength
Genome-wide association studies cataloged in the [GWAS Catalog](https://www.ebi.ac.uk/gwas/search?query=rs634062) have consistently tied the IL33 locus to allergic diseases, elevated eosinophil counts, childhood asthma, and airway hypersensitivity. Specific candidate gene and locus-level investigations have linked the rs634062 minor allele to enhanced IL33 expression, conferring modest statistical associations with allergic rhinitis, atopic dermatitis, and food allergies such as peanut allergy. However, the scientific evidence for rs634062 as an independent causal driver remains limited. Because the IL33 locus exhibits dense linkage disequilibrium, many neighboring variants—such as rs1888909 and rs992969—also associate strongly with type 2 inflammatory traits in peer-reviewed literature indexed on [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=rs634062). As a result, rs634062 may reflect a surrogate marker for broader regulatory haplotypes rather than the sole functional switch.
Population Frequency and Ancestral Distribution
The rs634062 polymorphism is relatively common across global populations, though its distribution exhibits ancestral variability. Based on reference data from global human genome projects and catalog metrics, the minor allele maintains a frequency of approximately 0.20 to 0.30 across European and East Asian cohorts, meaning that a significant portion of individuals in these groups carry at least one copy of the variant. In contrast, allele frequencies can differ markedly in African and admixed American populations due to differing ancestral linkage disequilibrium architectures across chromosome 9. This natural variation across global backgrounds emphasizes why genetic association findings cannot be generalized uniformly without evaluating diverse population cohorts.
Practical Implications and Clinical Perspective
Carrying an allele associated with increased IL33 expression does not mean a person will inevitably develop allergies, eczema, or asthma. Allergic and atopic diseases are complex, multifactorial traits driven by interactions between numerous small-effect genes and environmental triggers, such as viral infections, allergen exposures, diet, and microbiome balance. A consumer genetic test identifying rs634062 cannot be used as a standalone diagnostic tool, nor can it predict disease severity. Individuals with personal or family histories of chronic allergic symptoms or respiratory conditions should discuss their symptoms and management strategies with a physician or allergy specialist rather than attempting to self-diagnose or modify treatments based solely on genetic marker data.
How common is this variant?
The minor allele frequency for rs634062 is approximately 0.20 to 0.30 in European and East Asian cohorts, with varying distributions across other global ancestral populations.
Frequently asked questions
Does having the rs634062 risk genotype guarantee I will get allergies?
No. The rs634062 variant contributes only a modest statistical association to overall risk, not a direct cause. Many individuals who carry the minor allele never develop allergic rhinitis, eczema, or food allergies, because complex conditions depend heavily on environmental exposures and hundreds of other genetic factors.
Can testing for rs634062 diagnose asthma or eczema?
No, genetic testing for this single-nucleotide polymorphism is not a diagnostic test. Clinical diagnoses of allergic diseases and asthma are made by medical professionals through clinical history, physical exams, spirometry, and standard allergy testing.
What does an alarmin cytokine like IL-33 actually do?
Interleukin-33 acts as an early danger signal stored within epithelial cells that line the skin and respiratory tract. When these tissues encounter damage or allergens, IL-33 is released to alert and activate the immune system, initiating a type 2 inflammatory defense.
Are there targeted medical treatments available for the IL-33 pathway?
Researchers have investigated biologic therapies that target the IL-33/ST2 signaling pathway for severe asthma and other inflammatory disorders. However, these specialized therapies are prescribed based on specific clinical diagnoses and disease severity, not directly based on an individual's personal rs634062 genotype.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs634062?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IL33
An intronic regulatory polymorphism in IL33 that influences expression levels and predisposes carriers to allergic rhinitis and atopic sensitization.
Interleukin-33 promoter variant modulating cytokine expression and predisposition to environmental allergies.
Upstream regulatory variant affecting IL-33 expression, linked to asthma and atopic phenotypes.
Variant in IL33 associated with asthma and allergic sensitization.
This variant located near the IL33 gene is associated with an increased risk of nasal polyposis, particularly in patients with eosinophilia.